Berenberg Bank Reiterates Buy Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by analysts at Berenberg Bank in a research report issued on Thursday, Marketbeat Ratings reports. They presently have a GBX 2,300 price target on the stock. Berenberg Bank’s target price suggests a potential upside of 48.01% from the company’s previous close.

HIK has been the topic of several other reports. JPMorgan Chase & Co. decreased their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a research report on Friday, November 7th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating for the company in a research note on Friday, January 9th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Finally, Peel Hunt reissued a “buy” rating and issued a GBX 2,170 target price on shares of Hikma Pharmaceuticals in a report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of GBX 2,326.

Hikma Pharmaceuticals Stock Down 0.9%

HIK opened at GBX 1,554 on Thursday. The company has a market capitalization of £3.44 billion, a P/E ratio of 9.31, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The firm’s fifty day moving average price is GBX 1,551.34 and its two-hundred day moving average price is GBX 1,708.95. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,482 and a fifty-two week high of GBX 2,360.

Insider Transactions at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Victoria Hull purchased 3,214 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was purchased at an average cost of GBX 1,547 per share, with a total value of £49,720.58. Also, insider Mazen Darwazah acquired 315,000 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was acquired at an average price of GBX 1,601 per share, with a total value of £5,043,150. Over the last 90 days, insiders bought 448,214 shares of company stock valued at $712,497,058. Corporate insiders own 18.15% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.